1616923-01-3

Upstream product

• 1616923-00-2 5-(benzyloxy)-2-((1-(4-chlorophenyl)cyclopentyl)methyl)-6-hydroxy-N-(2-hydroxyethyl)-N-(1,1,1-trifluoropropan-2-yl)pyrimidine-4-carboxamide 
• 1616922-98-5 N-(2-(tert-butyldimethylsilyloxy)ethyl)-1,1,1-trifluoropropan-2-amine 
• 42977-90-2 2-(1,1,1-trifluoropropan-2-ylamino)ethanol 
• 42978-06-3 2-methyl-2-(trifluoromethyl)oxazolidine 
• 1616922-99-6 5-(benzyloxy)-N-(2-(tert-butyldimethylsilyloxy)ethyl)-2-((1-(4-chlorophenyl)cyclopentyl)methyl)-6-hydroxy-N-(1,1,1-trifluoropropan-2-yl)pyrimidine-4-carboxamide 
• 31600-43-8 methyl 2-(benzyloxy)acetate 
• 30379-55-6 benzyloxyacetic acid 
• 1616922-84-9 5-benzyloxy-2-[1-(4-chlorophenyl)cyclopentylmethyl]-6-hydroxypyrimidine-4-carboxylic acid 
• 1616922-82-7 5-benzyloxy-2-[1-(4-chlorophenyl)cyclopentylmethyl]-6-hydroxypyrimidine-4-carboxylic acid tert-butyl ester 

Downstream Products

• 1616921-74-4 6-((1-(4-chlorophenyl)cyclopentyl)methyl)-9-hydroxy-2-(1,1,1-trifluoropropan-2-yl)-3,4-dihydro-1H-pyrazino[1,2-c]pyrimidine-1,8(2H)-dione 

Relevant academic research and scientific papers

PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.